Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc. Frequently Asked Questions
What is the ticker symbol for Context Therapeutics Inc.? What does CNTX stand for in stocks?
CNTX is the stock ticker symbol of Context Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Context Therapeutics Inc. (CNTX)?
As of Fri Nov 22 2024, market cap of Context Therapeutics Inc. is 105 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of CNTX stock?
You can check CNTX's fair value in chart for subscribers.
Is Context Therapeutics Inc. a good stock to buy?
The fair value guage provides a quick view whether CNTX is over valued or under valued. Whether Context Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Context Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNTX.